AstraZeneca and Moderna Therapeutics announce exclusive agreement to develop pioneering messenger RNA Therapeutics™ in cardiometabolic diseases and cancer

AstraZeneca and Moderna Therapeutics announce exclusive agreement to develop pioneering messenger RNA Therapeutics™ in cardiometabolic diseases and cancer

March 21, 2013

 

AstraZeneca today announced an exclusive agreement with Moderna Therapeutics to discover, develop and commercialise pioneering messenger RNA therapeutics™ for the treatment of serious cardiovascular, metabolic and renal diseases as well as cancer. Messenger RNA therapeutics™ are an entirely new treatment approach that enables the body to produce therapeutic protein in vivo, opening up new treatment options for a wide range of diseases that cannot be addressed today using existing technologies.

Flagship Ventures and Merck Research Labs Form Strategic Collaboration to Foster Early-Stage Life Sciences Innovation

Flagship Ventures and Merck Research Labs Form Strategic Collaboration to Foster Early-Stage Life Sciences Innovation

April 10, 2012

Initiative combines Merck’s drug development expertise with Flagship’s experience in building early stage companies

Joule to Team with DNV GL for Commercial Validation of Transformative CO2-to-Fuels Production Process

Joule to Team with DNV GL for Commercial Validation of Transformative CO2-to-Fuels Production Process

September 17, 2014

Bedford, MA, USA – September 17, 2014 – Joule, the pioneer of direct, solar conversion of CO2 to liquid fuels, today announced that it has entered into a memorandum of understanding (MoU) with DNV GL, a leading provider of technical assurance and advisory services to the energy industry. The next step will be to define the specific areas of collaboration that will accelerate the global production of CO2-neutral fuels.

Dr. Mark Roskey Joins Quanterix Leadership Team

Dr. Mark Roskey Joins Quanterix Leadership Team

September 16, 2014

LEXINGTON, Mass.--(BUSINESS WIRE)--

Concert Pharmaceuticals Announces Initiation of CTP-730 Phase 1 Clinical Trial Under Celgene Collaboration

Concert Pharmaceuticals Announces Initiation of CTP-730 Phase 1 Clinical Trial Under Celgene Collaboration

September 17, 2014

LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated a Phase 1 clinical trial of CTP-730, a novel product candidate that is being developed under its strategic collaboration with Celgene Corporation. Concert will conduct the randomized, double-blind, single ascending dose Phase 1 clinical trial designed to assess the safety, tolerability and pharmacokinetics of CTP-730. The study is expected to enroll up to 40 healthy subjects.

Seres Health Presents Final Data for Study of SER-109 in Recurrent Clostridium difficile Infection at ICAAC 2014 Conference

Seres Health Presents Final Data for Study of SER-109 in Recurrent Clostridium difficile Infection at ICAAC 2014 Conference

September 8, 2014

Phase I/II study also demonstrated SER-109 restoration of a diverse, healthy microbiome

CPI Announces Finalists For 2013 Polyurethane Innovation Award

CPI Announces Finalists For 2013 Polyurethane Innovation Award

September 5, 2014

BASF Corporation, Dow and Novomer, Inc., Named Finalists

Joule and Scatec Solar ASA to Align for Photovoltaic-Powered Solar Fuel Production

Joule and Scatec Solar ASA to Align for Photovoltaic-Powered Solar Fuel Production

September 5, 2014

Bedford, MA - Joule, the pioneer of the direct, solar conversion of CO2 into liquid fuels, today announced that it has entered into a memorandum of understanding (MoU) with Scatec Solar ASA, a leading, independent solar power producer. In the MoU the parties have agreed to initiate a process to reach specific terms for a partnership, to support the roll-out of Joule production plants featuring photovoltaic power.

BIND Therapeutics Appoints Two New Board Members

BIND Therapeutics Appoints Two New Board Members

September 3, 2014

- Industry leaders, Eric K. Rowinsky, M.D. and Amy W. Schulman, join BIND's Board of Directors -

Avedro Acquires Assets of IROC Innocross AG, Including its UV-X Line of Cross-Linking Devices

Avedro Acquires Assets of IROC Innocross AG, Including its UV-X Line of Cross-Linking Devices

September 3, 2014

Avedro and IROC Innocross Are the World's Leading Corneal Cross-Linking Device Companies

Waltham, Massachusetts, USA, Sep 03, 2014 Avedro Inc., a Boston-based ophthalmic medical device and pharmaceutical company announces today that it has purchased the assets of IROC Innocross AG, of Zug, Switzerland.